Marlies M Kok

List of Publications by Year
in descending order

30	899	567281 15	477307 29
papers	citations	h-index	g-index

34	34	34	1319
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet, The, 2016, 388, 2607-2617.	13.7	208
2	Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobaltâ€“chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. Lancet, The, 2018, 392, 1235-1245.	13.7	112
3	Patient preference for radial versus femoral vascular access for elective coronary procedures: The PREVAS study. Catheterization and Cardiovascular Interventions, 2018, 91, 17-24.	1.7	75
4	Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels. JAMA Cardiology, 2019, 4, 659.	6.1	56
5	Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial. American Heart Journal, 2016, 176, 28-35.	2.7	55
6	Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2019, 12, 1650-1660.	2.9	44
7	Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients. JAMA Cardiology, 2017, 2, 268.	6.1	42
8	5-Year Outcome Following RandomizedÂTreatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents. JACC: Cardiovascular Interventions, 2018, 11, 462-469.	2.9	41
9	Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents. American Heart Journal, 2016, 175, 121-129.	2.7	39
10	Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial. EuroIntervention, 2018, 14, 915-923.	3.2	38
11	Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes. Journal of Cardiology, 2017, 69, 660-665.	1.9	25
12	â€œSilentâ€•Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 448-459.	2.9	22
13	High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT. International Journal of Cardiology, 2018, 268, 11-17.	1.7	19
14	Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial. American Heart Journal, 2015, 169, 69-77.	2.7	18
15	Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 553-561.	2.9	18
16	Are component endpoints equal? A preference study into the practice of composite endpoints in clinical trials. Health Expectations, 2018, 21, 1046-1055.	2.6	12
17	Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials. Cardiovascular Diabetology, 2021, 20, 217.	6.8	11
18	Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial. Clinical Research in Cardiology, 2016, 105, 206-215.	3.3	8

#	Article	IF	Citations
19	Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial. American Heart Journal, 2018, 198, 25-32.	2.7	8
20	Threeâ€year clinical outcome in allâ€comers with â€œsilentâ€•diabetes, prediabetes, or normoglycemia, treated with contemporary coronary drugâ€eluting stents: From the BIOâ€RESORT Silent Diabetes study. Catheterization and Cardiovascular Interventions, 2020, 96, E110-E118.	1.7	8
21	High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial. Cardiovascular Drugs and Therapy, 2018, 32, 567-576.	2.6	7
22	Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial. Heart and Vessels, 2016, 31, 1731-1739.	1.2	6
23	Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial. Catheterization and Cardiovascular Interventions, 2021, 98, E188-E196.	1.7	6
24	Longâ€Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newerâ€Generation Drugâ€Eluting Stents. Journal of the American Heart Association, 2018, 7, .	3.7	5
25	Treating diabetic all-comers with contemporary drug-eluting stents: Prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials. International Journal of Cardiology, 2021, 325, 37-44.	1.7	5
26	Involving the patientâ€™s perspective and preferences concerning coronary angiography and percutaneous coronary intervention. EuroIntervention, 2020, 15, 1228-1231.	3.2	4
27	New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trials. American Heart Journal, 2020, 228, 109-115.	2.7	3
28	Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study. EuroIntervention, 2016, 11, 1487-1494.	3.2	3
29	Serial assessment of endothelial function 1, 6, and 12Âmonths after ST-elevation myocardial infarction. Heart and Vessels, 2018, 33, 978-985.	1.2	1
30	TCT-570 3-Year Clinical Outcome of the DUTCH PEERS (TWENTE II) Randomized Trial: Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Versus Platinum-Chromium Everolimus-Eluting Promus Element Stents in All-Comer Patients. Journal of the American College of Cardiology, 2015, 66, B231.	2.8	0